Main Article Content
To compare the efficacy of Myo-inositol versus Metformin on clinical, hormonal and metabolic profile while treating women with Polycystic Ovary Syndrome. Compared with Metformin, Myo-inositol significantly reduced serum fasting insulin levels and HOMA-IR (p- value <0.05). 65 % of patients in the Metformin group had side-effects, mainly gastrointestinal disturbances, whereas only 12% in Myo-inositol had side effects. Owing to better therapeutic efficacy, safety and tolerability profile, the observations of the present study justify the use of Myo-inositol as a safe, effective alternative and a new addition in the armamentarium of PCOS treatment.